A5033552897- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Advancements in Photolithography Techniques
- Helicobacter pylori-related gastroenterology studies
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Treatments and Mutations
- Integrated Circuits and Semiconductor Failure Analysis
- Cancer Genomics and Diagnostics
- Hydrology and Watershed Management Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastroesophageal reflux and treatments
- Cancer Treatment and Pharmacology
- Electron and X-Ray Spectroscopy Techniques
- Advanced Surface Polishing Techniques
- Pancreatic and Hepatic Oncology Research
- Drug Transport and Resistance Mechanisms
- Metastasis and carcinoma case studies
- Semiconductor materials and devices
- Esophageal and GI Pathology
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
Kindai University
2015-2024
Nara Medical University Hospital
2018-2024
Tokushima University
1999-2023
Osaka International Cancer Institute
2020
Weatherford College
2020
Kindai University Hospital
2015-2019
Shikoku (Japan)
2018
Shikoku Central Hospital of the Mutual Aid Association of Public School Teachers
2016-2018
Kobe University
2007-2016
Saitama Cancer Center
2014
Nivolumab showed improvement in overall survival (OS) ATTRACTION-2, the first phase 3 study patients with gastric/gastroesophageal junction (G/GEJ) cancer treated ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein.ATTRACTION-2 was a randomized, double-blind, placebo-controlled, trial (49 sites; Japan, South Korea, and Taiwan). median (min-max) period 27.3 (24.1-36.3) months. primary endpoint OS. A subanalysis OS performed based on best response...
The effect of the C3435T mutation at exon 26 MDR1 gene on expression levels messenger ribonucleic acid (mRNA) was evaluated by means real-time polymerase chain reaction in 51 biopsy specimens duodenum obtained from 13 healthy Japanese subjects. mRNA were 0.38 +/- 0.15, 0.56 0.14, and 1.13 0.42 (mean value SE) subjects with homozygote wild-type allele (C/C), compound heterozygote mutant T (C/T), (T/T), respectively, reasonably explaining lower digoxin serum concentration after administration...
Anti‐HER2 therapies are beneficial for patients with HER2‐positive breast or gastric cancer. T‐DM1 is a HER2‐targeting antibody–drug conjugate (ADC) comprising the antibody trastuzumab, linker, and tubulin inhibitor DM1. Although effective in treating advanced cancer, all eventually develop resistance. DS‐8201a new ADC incorporating an anti‐HER2 antibody, newly developed, enzymatically cleavable peptide novel, potent, exatecan‐derivative topoisomerase I (DXd). has drug‐to‐antibody‐ratio...
Nephrotoxicity remains a problem for patients who receive cisplatin chemotherapy. We retrospectively evaluated potential risk factors cisplatin-induced nephrotoxicity as well the impact of intravenous magnesium supplementation on such toxicity.We reviewed clinical data 401 underwent chemotherapy including high dose (≥60 mg/m2) in first-line setting. was defined an increase serum creatinine concentration at least grade 2 during first course chemotherapy, assessed basis National Cancer...
2 Background: Recent clinical trials have established 1 st and nd line chemotherapy as the standard treatment for advanced gastric or gastro-esophageal junction cancer (AGC). However, prognosis of AGC is still poor. Nivolumab (ONO-4538/BMS-936558) a human monoclonal IgG4 antibody which blocks programmed cell death-1 (PD-1) receptor. We evaluated efficacy safety nivolumab salvage after failure AGC. Methods: 493 patients aged ≥ 20 years with ECOG PS 0-1 unresectable recurrent who had failed...
This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which these two drugs should be used as initial treatment.The data mCRC were treated or TFTD those drug-naive patients, between June 2014 September 2015, retrospectively collected from 24 institutions Japan. Overall survival (OS) was evaluated using...
ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated ≥ 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment beyond progression (TBP) have not been clarified.The 3-year follow-up data were collected. A subset analysis was performed to explore the TBP by assessing postprogression (PPS) after first event disease progression.Overall, 493 randomized (2:1) receive (n = 330) or 163). With a...
Recent years have witnessed a decrease in the rate of Helicobacter pylori eradication due to antimicrobial resistance, clarithromycin or metronidazole resistance particular. As one alternatives standard regimens, levofloxacin-containing therapy has been considered promising regimen. Nevertheless, there is little information concerning prevalence levofloxacin and this mechanism.Levofloxacin susceptibility was examined using E-test 507 H. strains clinically isolated Japan from 2001 2004....
In the present study, we examined whether polymorphisms in ATP-binding cassette (ABC) transporter genes, MDR1, MRP1 and MRP2, were associated with their respective mRNA expression levels duodenal enterocytes of 13 healthy Japanese volunteers. MDR1 genotypes T-129C, G2677(A,T) C3435T, G128C, C218T, G2168A G3173A, MRP2 C-24T, G1249A, C2302T, C2366T G4348A determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or direct sequencing. Mutations C3435T gene...
The expression levels of mRNAs for MDR1 (P-glycoprotein), multidrug resistance-associated proteins (MRP1, MRP2), and cytochrome P450 3A (CYP3A) in Caco-2 cells were quantitatively compared with those human duodenal enterocytes, normal colorectal tissues, adenocarcinomas. (passages 36–88) kindly supplied by several laboratories Japan. Human enterocytes obtained from five healthy male volunteers. Normal tissues adenocarcinomas simultaneously seven patients primary adenocarcinoma. MDR1, MRP1,...
The Trastuzumab for Gastric Cancer (ToGA) study is the first international trial to include Japanese patients with human epidermal growth factor 2 (HER2) positive advanced/metastatic gastric or gastroesophageal junction cancer. ToGA showed that trastuzumab plus chemotherapy (capecitabine/cisplatin 5-fluorouracil/cisplatin) improved overall survival in population (hazard ratio 0.74). Regional differences outcome favor of populations were observed other studies; therefore, subgroup analyses...
Nivolumab, an anti-programmed death-1 agent, showed survival benefits in Asian patients, including Japanese, with gastric/gastro-esophageal junction (G/GEJ) cancer. We report the analysis of Japanese subpopulation from ATTRACTION-2 that evaluated nivolumab versus placebo unresectable advanced or recurrent G/GEJ cancer after ≥ 2 chemotherapy regimens. Data randomized, double-blind, placebo-controlled, phase 3 trial were analyzed (data cutoff, February 25, 2017). Primary endpoint was overall...
Abstract Background. In advanced gastric cancer (AGC), no globally accepted prognostic scoring system has been developed. Therefore, we explored baseline factors in Japanese AGC patients using the data from a randomized controlled trial, Japan Clinical Oncology Group (JCOG) 9912, which investigated efficacy of systemic chemotherapy as first-line treatment. Patients and Methods. Prognostic indices for overall survival were screened evaluated enrolled JCOG9912 Cox proportional hazard model....